XML 27 R15.htm IDEA: XBRL DOCUMENT v3.25.3
Goodwill and Intangible Assets, Net
 9 Months Ended
Sep. 30, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, Net Goodwill and Intangible Assets, Net
Goodwill
The following table sets forth the gross carrying amounts of goodwill (dollars in thousands):
Balance as of December 31, 2024
$117,019 
Goodwill from Sage Acquisition
2,061 
Balance as of September 30, 2025 (unaudited)
$119,080 
The increase in goodwill is from the Sage Acquisition. See Note 3, Sage Acquisition, for further discussion.
Intangible Assets, Net
The following table sets forth the gross carrying amounts and related accumulated amortization of intangible assets (dollars in thousands):
September 30, 2025December 31, 2024
(unaudited)
Remaining Weighted
Average Life (Years)		Carrying Amount, GrossAccumulated AmortizationCarrying Amount, NetCarrying Amount, GrossAccumulated AmortizationCarrying Amount, Net
Acquired in-process research and development$— $— $— $124,000 $— $124,000 
Intangible assets subject to amortization:
Acquired developed technology and product rights6.6951,811 (328,330)623,481 661,311 (263,399)397,912 
Capitalized patent defense costs—43,820 (43,820)— 43,820 (43,820)— 
Total intangible assets6.6$995,631 $(372,150)$623,481 $829,131 $(307,219)$521,912 
Amortization expense for intangible assets was $24.3 million and $64.9 million for the three and nine months ended September 30, 2025, and $19.5 million and $59.7 million for the three and nine months ended September 30, 2024, respectively.
In February 2025, the FDA approved ONAPGO and as such, the research and development efforts for the Company's acquired in-process research and development asset is considered complete. As of the FDA approval date, the ONAPGO intangible asset is a definite-life intangible asset subject to amortization and has a useful life of 10 years.
In July 2025, the Company acquired ZURZUVAE® (zuranolone), the first and only FDA-approved oral medicine indicated for the treatment of PPD in adults. The ZURZUVAE intangible asset is a definite-lived intangible asset subject to amortization and has a useful life of 8 years.
U.S. patents covering Trokendi XR and Oxtellar XR will expire no earlier than 2027. The Company entered into settlement agreements that allowed third parties to enter the Trokendi XR market on January 1, 2023. The Company entered into settlement and license agreements that allowed a third party to enter the Oxtellar XR market in September 2024.
The Company entered into settlement and license agreements that allows third parties to enter the XADAGO market in December 2027, or sooner under certain conditions.